 MENLO PARK, Calif. BOSTON--BUSINESS WIRE--Adicet Bio, Inc. Nasdaq: ACET, a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor CAR T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. Wainwright Global Investment Conference, May 23-26, 2022 An on-demand presentation will be available 